PMID- 37752751 OWN - NLM STAT- MEDLINE DCOM- 20231204 LR - 20240201 IS - 1532-2491 (Electronic) IS - 1082-6084 (Print) IS - 1082-6084 (Linking) VI - 59 IP - 1 DP - 2024 TI - Resilience Phenotypes and Psychological Functioning among Individuals with Opioid Use Disorder. PG - 41-49 LID - 10.1080/10826084.2023.2259450 [doi] AB - BACKGROUND: Opioid use disorder (OUD) is a heterogeneous disorder. However, there is a lack of deep phenotyping investigations focusing on important psychological constructs such as resilience that may impact OUD. The present study aimed to investigate the relationship between trait resilience and the five-factor model of personality (FFM) among individuals with opioid use disorder (OUD). We also explored whether the FFM and trait resilience form specific phenotypes associated with psychological functioning. METHODS: This secondary analysis of an epigenetic study included participants of African ancestry (n = 72), an understudied population, who met DSM-5 criteria for OUD. Participants completed measures to assess personality traits, trait resilience, current and previous drug use, and psychological functioning (depression, anxiety, and stress). RESULTS: Linear regression revealed a significant relationship between resilience (CD-RISC-25 score) and the FFM, R(2) = 0.56, F(5,62) = 15.7, p<.001. Further, a two-cluster classification emerged as the optimal solution from the cluster analysis. Cluster 1 (n = 33, 45.8% of the sample) showed lower resilience (CD-RISC-25 score: M = 58.6, SD = 11.2) compared to Cluster 2 (n = 35, 48.6%; CD-RISC-25 score: M = 76.1, SD = 11.9). The "High-Resilience Cluster" (Cluster 2) was characterized by higher FFM traits of: Extraversion, Openness, Agreeableness, and Conscientiousness, and lower Neuroticism versus Cluster 1. Multivariate analysis of variance revealed statistically significant differences between the two resilience clusters concerning other psychological symptoms, Lambda = 0.732, F(4, 50) = 7.05, p < 0.003. CONCLUSIONS: These findings suggest associations between the FFM and trait resilience among individuals with OUD. Two distinct "resilience phenotypes" emerged, with high-resilience individuals displaying less stress, anxiety, and depressive symptoms. Results highlight the clinical importance of resilience as a potential target for intervention in people with OUD. FAU - Martinez, Suky AU - Martinez S AUID- ORCID: 0000-0002-4873-8130 AD - Division on Substance Use Disorders, Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons and New York State Psychiatric Institute, New York, New York, USA. FAU - Garcia-Romeu, Albert AU - Garcia-Romeu A AUID- ORCID: 0000-0003-2182-1644 AD - Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. FAU - Perez, Freymon AU - Perez F AD - Division on Substance Use Disorders, Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons and New York State Psychiatric Institute, New York, New York, USA. FAU - Jones, Jermaine D AU - Jones JD AUID- ORCID: 0000-0003-4476-2800 AD - Division on Substance Use Disorders, Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons and New York State Psychiatric Institute, New York, New York, USA. LA - eng GR - R21 DA043199/DA/NIDA NIH HHS/United States GR - T32 DA007294/DA/NIDA NIH HHS/United States PT - Journal Article DEP - 20231201 PL - England TA - Subst Use Misuse JT - Substance use & misuse JID - 9602153 SB - IM MH - Humans MH - Personality Inventory MH - Personality MH - Personality Disorders/diagnosis MH - Phenotype MH - *Opioid-Related Disorders MH - *Resilience, Psychological PMC - PMC10829514 MID - NIHMS1939099 OTO - NOTNLM OT - Resilience OT - five factor model of personality OT - heroin OT - heterogeneity OT - opioid use disorder COIS- Declaration of Interest Within the past three years, Dr. Jones received compensation (in the form of partial salary support) from a study partially supported by Cerecor Inc and has served as a paid consultant to Alkermes and the World Health Organization. Dr. Garcia-Romeu is a paid scientific advisor to ETHA Natural Botanicals and NeonMind Biosciences and has received research funding from the Heffter Research Institute, Unlimited Sciences, and MicroDoz Therapy Inc. Dr. Martinez and Mr. Perez have no conflicts to report. EDAT- 2023/09/27 06:42 MHDA- 2023/12/04 12:43 PMCR- 2025/01/01 CRDT- 2023/09/27 02:03 PHST- 2025/01/01 00:00 [pmc-release] PHST- 2023/12/04 12:43 [medline] PHST- 2023/09/27 06:42 [pubmed] PHST- 2023/09/27 02:03 [entrez] AID - 10.1080/10826084.2023.2259450 [doi] PST - ppublish SO - Subst Use Misuse. 2024;59(1):41-49. doi: 10.1080/10826084.2023.2259450. Epub 2023 Dec 1.